Email this article Oral fluorpyrimidines in preoperative chemoradiotherapy for operable rectal cancer
- Authors: Barsukov Y.A.1, Tkachyov S.I.1, Malikhov A.G.1, Gordeev S.S.1, Perevoshchikov A.G.1, Aliev V.A.1, Kuz'michyov D.V.1, Tataev I.S.1, Mad'yarov Z.M.1, Ovchinnikova A.I.1, Kovalyova Y.Y.1
-
Affiliations:
- N.N. Blokhin Russian Cancer Research Center, Ministry of Health of Russia
- Issue: Vol 5, No 4 (2015)
- Pages: 24-30
- Section: ORIGINAL REPORTS
- Published: 15.01.2016
- URL: https://onco-surgery.info/jour/article/view/149
- DOI: https://doi.org/10.17650/2220-3478-2015-5-4-24-30
- ID: 149
Cite item
Full Text
Abstract
Background. The aim of this study was to compare short and long-term outcomes after neoadjuvant short-course chemoradiotherapy with capecitabine ot tegafur for operable rectal cancer.
Materials and methods. Patients with histologycally verified Т3N0M0, Т2–3N1–2M0 rectal cancer, who underwent 5 × 5 Gy neoadjuvant radiotherapy with local 41–45 °C hyperthermia on days 3–5 and metronidazole 10 g/m2 per rectum days 3, 5 were randomized to receive capecitabine 1000 mg/m2 bid per os days 1–14 or tegafur 400 mg/m2 bid per os days 1–21. Toxicity, tumor regression, sphincter preservation rate and long-term outcomes were analyzed.
Results. During 2011–2013 26 patients were included in the tegafur group and 30 – in capecitabine group. Overall toxicity was 50 % in the tegafur arm and 36.7 % in the capecitabine arm (p = 0.42), grade III–IV toxicity (diarrhoea was the most common grade 3+ event) was observed in 23.1 % and 6.7 % (p = 0.13) patients accordingly. Grade III–IV tumor regression was observed in 34.6 % patients, who received tegafur and 53.3 % (p = 0.12) patients who received capecitabine. Sphincter-sparing surgery was performed in 84.6 % and 100 % (p = 0.04) patients who received tegafur and capecitabine accordingly. Median follow-up was 31.6 and 32.2 months accordingly. 3-year overall survival in capecitabine and tegafur arms was 95.4 and 82.1 % (р = 0.13), 3-year disease-free survival – 91 and 74 % (р = 0.029).
Conclusions. Both fluorpyrimidines demonstrated comparable short-term outcomes with a tendency to better results in the capecitabine arm.
About the authors
Yu. A. Barsukov
N.N. Blokhin Russian Cancer Research Center, Ministry of Health of Russia23 Kashirskoe Shosse, Moscow, 115478 Russian Federation
S. I. Tkachyov
N.N. Blokhin Russian Cancer Research Center, Ministry of Health of Russia23 Kashirskoe Shosse, Moscow, 115478 Russian Federation
A. G. Malikhov
N.N. Blokhin Russian Cancer Research Center, Ministry of Health of Russia23 Kashirskoe Shosse, Moscow, 115478 Russian Federation
S. S. Gordeev
N.N. Blokhin Russian Cancer Research Center, Ministry of Health of Russia
Author for correspondence.
Email: ss.netoncology@gmail.com
23 Kashirskoe Shosse, Moscow, 115478 Russian Federation
A. G. Perevoshchikov
N.N. Blokhin Russian Cancer Research Center, Ministry of Health of Russia23 Kashirskoe Shosse, Moscow, 115478 Russian Federation
V. A. Aliev
N.N. Blokhin Russian Cancer Research Center, Ministry of Health of Russia23 Kashirskoe Shosse, Moscow, 115478 Russian Federation
D. V. Kuz'michyov
N.N. Blokhin Russian Cancer Research Center, Ministry of Health of Russia23 Kashirskoe Shosse, Moscow, 115478 Russian Federation
I. Sh. Tataev
N.N. Blokhin Russian Cancer Research Center, Ministry of Health of Russia23 Kashirskoe Shosse, Moscow, 115478 Russian Federation
Zh. M. Mad'yarov
N.N. Blokhin Russian Cancer Research Center, Ministry of Health of Russia23 Kashirskoe Shosse, Moscow, 115478 Russian Federation
A. I. Ovchinnikova
N.N. Blokhin Russian Cancer Research Center, Ministry of Health of Russia23 Kashirskoe Shosse, Moscow, 115478 Russian Federation
Yu. Yu. Kovalyova
N.N. Blokhin Russian Cancer Research Center, Ministry of Health of Russia23 Kashirskoe Shosse, Moscow, 115478 Russian Federation
References
Supplementary files
